The World Health Organization (WHO) has commenced a groundbreaking clinical trial to assess the efficacy of the Ervebo vaccine in response to a severe Ebola outbreak in the Democratic Republic of Congo (DRC). This announcement was made by WHO Director-General Tedros Adhanom Ghebreyesus via social media, emphasizing the need for effective solutions in the affected regions.

Details of the Clinical Trial

The trial is taking place in Bunia, the capital of Ituri province, which is currently the epicenter of the ongoing outbreak. Ervebo, approved for use against the Zaire strain of Ebola, will be evaluated for its potential cross-protection against the Bundibugyo strain, which has been linked to the current epidemic.

“This trial will help us understand whether any of the vaccine candidates designed for Bundibugyo virus work,” stated Ghebreyesus, highlighting the urgency of the situation.

Current Outbreak Status

Since its declaration in May, the DRC has reported over 9,700 cases, with fatalities exceeding 4,600. This outbreak is characterized by its unprecedented spread, having been documented across four countries in Africa, the widest geographical reach of any Ebola outbreak on the continent.

In response, the WHO has declared a public health emergency of international concern, its second-highest alert level, underscoring the critical nature of the epidemic.

Innovative Approach to Vaccination

The trial, dubbed the Tumaini trial, will utilize a comprehensive framework designed to evaluate the safety, efficacy, and immunogenicity of various vaccine candidates. A unique aspect of this study is its ring vaccination approach, targeting individuals with high exposure risk.

Alongside Ervebo, two additional Bundibugyo-specific vaccine candidates will also be tested. One candidate is a ChAdOx1 adenoviral vector vaccine developed by the University of Oxford, while the other, utilizing mRNA technology, is the work of the US-based Moderna group. Both candidates have received backing from the Coalition for Epidemic Preparedness Innovations (CEPI) and are anticipated to begin the trial soon.

Inclusive Clinical Trial Design

Significantly, this trial will include diverse populations, such as pregnant women and children aged 12 and older, which are often underrepresented in clinical research. WHO emergencies director Chikwe Ihekweazu stated that the essential goal of the trial is to gather rigorous evidence to determine the level of protection these vaccines could offer to vulnerable populations at risk of Ebola infection.